Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Global X Uranium ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Iovance Biotherapeutics Inc. Common Stock and Global X Uranium ETF are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Global X Uranium ETF for 62 Days on average.
| IOVA | URA | |
|---|---|---|
Market Cap | $6.04B | $5.48B |
Volume | 14,805,993 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $14.82 | $61.81 |
52-Week Low | $1.81 | $37.52 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
URA, the Global X Uranium ETF, trades at $38.56, down 3.43% in the last session amid a bearish technical signal. Key support lies at $37, with resistance at $39. The fund provides exposure to uranium miners and nuclear energy companies, benefiting from structural supply deficits and rising demand for reliable power, particularly from AI data centers. Recent index additions like Terra Innovatum and Eagle Nuclear Energy reflect ongoing sector expansion.
The outlook for URA is mixed; long-term demand drivers from nuclear energy adoption and AI power needs are strong, but near-term price volatility and concentrated holdings pose risks. Investors should weigh the sector's growth potential against ETF-specific fluctuations and broader market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
